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Introduction: Although erlotinib, an orally active and selective
tyrosine kinase inhibitor of epidermal growth factor receptor, is
mainly metabolized in the liver, its effectiveness and safety for
patients with chronic renal failure (CRF) undergoing hemodialysis
(HD) has not been reported. Thus, we investigated the pharmacoki-
netics (PK) of erlotinib and its active metabolite OSI-420 in such
patients with nonsmall cell lung cancer (NSCLC).
Method: We administered 150 mg erlotinib daily to three patients
with NSCLC and CRF undergoing HD (HD group) and five patients
with NSCLC and normal organ function (control group) and ana-
lyzed the PK of erlotinib and OSI-420. In the HD group, PK
analyses were performed on day 1 (off HD), day 8 (off HD), and day
9 (on HD) after starting administration of erlotinib, and in the
control group, they were performed on day 1 and day 8.
Results: In the HD group, there were little differences in the PK data
between day 8 and day 9. The PK data on day 1 and day 8 of the HD
group were also similar to those of the control group. There were no
serious adverse events in any cases, and one of the HD patients
achieved partial response.
Conclusion: Erlotinib was hardly affected by renal function and
HD, which confirms the effectiveness and safety of erlotinib treat-
ment in patients with NSCLC and CRF undergoing HD. Erlotinib
can become one treatment option for such patients.
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Patients with chronic renal failure (CRF) undergoing he-modialysis (HD) are potentially at increased risk of cancer
for several reasons including the presence of chronic infec-
tion, weakened immune system, nutritional deficiencies, and
altered DNA repair.1 Although it is uncertain that patients
with CRF undergoing HD are at risk for lung cancer, more
patients undergoing HD will be diagnosed with lung cancer
because recent advances in HD have resulted in longer
survival than ever. Therefore, the treatment for patients with
lung cancer undergoing HD, who are frequently elderly and
have poor performance status (PS), becomes a more impor-
tant subject.
The epidermal growth factor receptor (EGFR) is rec-
ognized as an important molecular target in cancer therapy.2
Erlotinib is an orally active and potent inhibitor of the EGFR
tyrosine kinase (TKI). Compared with placebo, erlotinib
improved survival for patients with previously treated ad-
vanced nonsmall cell lung cancer (NSCLC) in a randomized
phase III trial.3 Moreover, the use of erlotinib for advanced
NSCLC in elderly or poor PS patients has been reported.4–7
There are also reports in which patients with CRF tolerate
normal doses (150 mg) of erlotinib daily8,9 and have an
erlotinib clearance similar to patients without organ dysfunc-
tion.9 Gridelli et al.8 reported safety profile of erlotinib in
patients with advanced NSCLC with CRF, however, the
safety of erlotinib treatment for patients with CRF undergo-
ing HD has not been reported. Here, erlotinib was adminis-
tered to three patients with NSCLC and CRF undergoing HD
(HD group) and five patients with NSCLC and normal organ
function (control group). We then compared the pharmaco-
kinetics (PK) data of erlotinib and its active metabolite
OSI-420 from the HD group with that of the control group.
PATIENTS AND METHODS
HD Group Case 1
A 74-year-old man ex-smoker with CRF, probably
because of nephrosclerosis, has undergone HD for 5 years.
The histology of lung cancer was adenocarcinoma without
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any EGFR mutations, and the stage was cT1N3M1. He had
Eastern Cooperative Oncology Group (ECOG) PS of 2 and
severe anemia caused by CRF. Therefore, we thought he
would get more benefit from an initial treatment with erlo-
tinib rather than cytotoxic chemotherapy.
HD Group Case 2
A 74-year-old woman nonsmoker with CRF because of
diabetes has undergone HD for 3 years. The histology of lung
cancer was adenocarcinoma without any EGFR mutations,
and the stage was cT2N0M0. After she first received irradi-
ation (54 Gy), the primary tumor got larger and invaded the
chest wall, with the ipsilateral hilar lymph node swollen
(cT3N1M0). She had an ECOG PS of 3 and severe anemia
caused by CRF, and she hoped to take erlotinib in the
first-line setting. Therefore, as with HD group case 1 (HD 1),
we considered erlotinib treatment rather than cytotoxic che-
motherapy.
HD Group Case 3
A 69-year-old man current smoker with CRF because
of diabetes has undergone HD for 1 year. The histology of
lung cancer was squamous cell carcinoma, and the stage was
cT2N1M1. EGFR mutations were not evaluated. He had an
ECOG PS of 2 and anemia because of CRF, and he hoped to
take erlotinib in the first-line setting. Therefore, as with HD
1 and HD group case 2 (HD 2), we considered erlotinib
treatment rather than cytotoxic chemotherapy.
After receiving their written informed consent from all
patients, they were administered 150 mg erlotinib daily with
HD three times a week. HD was performed for 4 hours using
a polysulfone membrane (APS; AsahiKASEI, Tokyo, Japan).
Control Group
Five patients with advanced NSCLC and normal organ
function were administered 150 mg erlotinib daily. Their
clinical characteristics are given in Table 1.
PK Analysis
In the HD group, we performed PK analyses of erlo-
tinib and OSI-420 on day 1 (off HD), day 8 (off HD), and day
9 (on HD) after starting administration of erlotinib. Blood
samples were obtained at 5 points a day: just before admin-
istration (C0); and then 2 hours (C2), 4 hours (C4), 8 hours
(C8), and 24 hours (C24) after administration. On day 9,
blood samples were obtained just before HD and just after
HD, as C4 and C8, respectively. In the control group, PK
analyses were performed on day 1 and day 8. The concen-
trations were determined by high-performance liquid chroma-
tography with ultraviolet detection as previously reported.10
Before analysis, we got written informed consent from all
patients.
RESULTS
HD Group Case 1
On day 1, the maximal plasma concentration (Cmax) of
erlotinib was 629 ng/ml and Cmax of OSI-420 was 29 ng/ml
at C2. C24 dropped to 305 ng/ml and 11 ng/ml, respectively
(Figure 1). The area under the plasma drug concentration-
time curve from 0 to 24 hours (AUC0–24) of erlotinib was
9378 ng/hr/ml, and AUC0–24 of OSI-420 was 386 ng/hr/ml
(Table 2).
On day 8, Cmax of erlotinib was 1521 ng/ml, and Cmax
of OSI-420 was 91 ng/ml at C2. C24 dropped to 849 ng/ml
and 52 ng/ml, respectively (Figure 1). AUC0–24 of erlotinib
was 25,627 ng/hr/ml, and AUC0–24 of OSI-420 was 1586
FIGURE 1. Plasma concentration-time plots of erlotinib
and OSI-420 in HD 1 on day 1 (off HD), day 8 (off HD) and
day 9 (on HD). Arrows indicate 150 mg erlotinib administra-
tion. HD, hemodialysis.
TABLE 1. Clinical Characteristics of All Patients (n  8)
Patient Age (yr) Sex PS Histology EGFR Mutation Stage Previous Treatment Smoking Status
HD 1 74 Male 2 Ad Wild type cT1N3M1 No Ex
HD 2 74 Female 3 Ad Wild type cT3N1M0 RT Never
HD 3 69 Male 2 Sq Not evaluated cT2N1M1 No Current
Control 1 52 Female 1 Ad Exon 19 746–750 deletion cT4N2M0 1 Chemotherapy Never
Control 2 68 Male 1 Ad Wild type cT1N2M1 2 Chemotherapies Ex
Control 3 69 Female 0 Ad Exon 21 L858R cT4N2M1 No Never
Control 4 75 Male 2 Sq Wild type cT4N2M0 2 Chemotherapies Ex
Control 5 59 Female 3 Ad Not evaluated cT4N3M1 3 Chemotherapies Never
PS, performance status; EGFR, epidermal growth factor receptor; HD, hemodialysis; Ad, adenocarcinoma; Sq, squamous cell carcinoma; RT, radiotherapy; Ex, ex-smoker; Never,
never smoker.
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ng/hr/ml (Table 2). These PK data were similar to those of
patients with normal organ function, which were previously
reported.11
On day 9, that is, on HD, C4 of erlotinib was 1283
ng/ml, and C8 was 1295 ng/ml. C4 of OSI-420 was 90 ng/ml
and C8 was 68 ng/ml (Figure 1). Although the PK patterns
were a little different from those on day 8, the PK parameters,
such as AUC0–24 or Cmax, were similar to those on day 8
(Table 2).
HD Group Case 2
On day 1, Cmax of erlotinib was 1112 ng/ml at C4, and
Cmax of OSI-420 was 100 ng/ml at C8. C24 dropped to 467
ng/ml and 61 ng/ml, respectively (Figure 2). AUC0–24 of
erlotinib was 18,559 ng hr/ml, and AUC0–24 of OSI-420 was
1774 ng/hr/ml (Table 2).
On day 8, Cmax of erlotinib was 1863 ng/ml at C2, and
Cmax of OSI-420 was 177 ng/ml at C8. C24 dropped to 452
ng/ml and 47 ng/ml, respectively (Figure 2). AUC0–24 of
erlotinib was 27,052 ng/hr/ml, and AUC0–24 of OSI-420 was
3042 ng/hr/ml (Table 2). These PK data were also similar to
those of patients with normal organ function, which were
previously reported.11
On day 9, that is, on HD, C4 of erlotinib was 1859
ng/ml and C8 was 1764 ng/ml. C4 of OSI-420 was 203 ng/ml
and C8 was 172 ng/ml (Figure 2). Although the PK patterns
were a little different from those on day 8, the PK parameters
were similar to those on day 8 (Table 2).
HD Group Case 3
On day 1, Cmax of erlotinib was 1139 ng/ml, and Cmax
of OSI-420 was 113 ng/ml at C2. C24 dropped to 242 ng/ml
and 19 ng/ml, respectively (Figure 3). AUC0–24 of erlotinib
was 13,896 ng/hr/ml, and AUC0–24 of OSI-420 was 1379
ng/hr/ml (Table 2).
On day 8, Cmax of erlotinib was 1459 ng/ml, and Cmax
of OSI-420 was 147 ng/ml at C2. C24 dropped to 182 ng/ml
and 12 ng/ml, respectively (Figure 3). AUC0–24 of erlotinib
was 17,177 ng/hr/ml, and AUC0–24 of OSI-420 was 1654
ng/hr/ml (Table 2). These PK data were also similar to those
FIGURE 2. Plasma concentration-time plots of erlotinib
and OSI-420 in HD 2 on day 1 (off HD), day 8 (off HD) and
day 9 (on HD). Arrows indicate 150 mg erlotinib administra-
tion. HD, hemodialysis.
FIGURE 3. Plasma concentration-time plots of erlotinib
and OSI-420 in HD 3 on day 1 (off HD), day 8 (off HD) and
day 9 (on HD). Arrows indicate 150 mg erlotinib administra-
tion. HD, hemodialysis.




(ng/hr/ml) Cmax (ng/ml) Tmax (hr) T1/2 (hr)
AUC0–24
(ng/hr/ml) Cmax (ng/ml) Tmax (hr) T1/2 (hr)
HD 1 1 9378 629 2 35.3 386 29 2 27.7
8 25,627 1521 2 45.4 1586 91 2 40.1
9 26,496 1794 2 16.3 1516 97 2 21.0
HD 2 1 18,559 1112 4 12.9 1774 100 8 22.5
8 27,052 1863 2 9.5 3042 177 8 8.4
9 33,325 1859 4 13.9 3444 203 4 20.3
HD 3 1 13,896 1139 2 10.4 1379 113 2 8.2
8 17,177 1459 2 6.7 1654 147 2 5.4
9 17,866 1244 4 8.5 1405 119 4 8.5
AUC0–24, area under the plasma drug concentration-time curve from 0 to 24 h; Cmax, maximal plasma concentration; Tmax, time to Cmax; T1/2, half period; HD, hemodialysis.
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of patients with normal organ function, which were previ-
ously reported.11
On day 9, that is, on HD, C4 of erlotinib was 1244
ng/ml and C8 was 1022 ng/ml. C4 of OSI-420 was 119 ng/ml
and C8 was 76 ng/ml (Figure 3). Although the PK patterns
were a little different from those on day 8, the PK parameters
were similar to those on day 8 (Table 2).
Control Group
As seen in Figure 3, the mean PK patterns were similar
to those previously reported.11 The PK data of the HD group
were similar to those of the control group.
The major toxicities in the first 4 weeks are listed in
Table 3. Although skin rash, dry skin, and diarrhea were the
principal toxicities associated with erlotinib, there were no
serious adverse events in any cases. Four weeks after admin-
istration, HD 1 and HD group case 3 (HD 3) achieved stable
disease, HD 2 achieved partial response, and four patients in
the control group achieved partial response (Table 3).
DISCUSSION
Erlotinib is metabolized in the liver, mainly by the
cytochrome CYP3A4 (80%), CYP1A1, and CYP1A2. Er-
lotinib and its metabolites are excreted predominantly
through the feces.12 The PK data of erlotinib and OSI-420 in
the HD group were similar to those in the control group and
patients with normal organ function as previously reported.11
In all cases, the PK parameters on day 9 were similar to those
on day 8, which indicated that erlotinib was little affected by
HD. This result is reasonable because 92 and 95% of erlotinib
in human plasma is combined with plasma proteins.12 How-
ever, the PK patterns of erlotinib on day 9 were a little
different from those on day 8. Although the definite reasons
are unclear, we can assume that erlotinib might be excreted in
tissues because they had hypoalbuminemia. Another reason
might be that they took different drugs (i.e., antihypertensive
drugs, etc.) on day 8 and on day 9. To our best knowledge,
this is the first report about PK of erlotinib and OSI-420 in
patients undergoing HD.
FIGURE 4. Mean plasma concen-
tration-time plots ( standard devi-
ation) of erlotinib and OSI-420 in
the control group on day 1 and day
8 and those in the HD group on
day 1, day 8, and day 9. HD shows
hemodialysis. The patterns in the
HD group were similar to those in
the control group.
TABLE 3. PK Parameters on Day 8, Major Toxicities in First 4 wk and Tumor Response 4 wk After Administration
Patient
Erlotinib OSI-420
Major Toxicities Tumor ResponseAUC0–24 (ng/hr/ml) Cmax (ng/ml) AUC0–24 (ng/hr/ml) Cmax (ng/ml)
HD 1 25,627 1521 1586 91 Diarrhea (G1) SD
HD 2 27,052 1863 3042 177 — PR
HD 3 17,177 1459 1654 147 Diarrhea (G1), nausea (G1) SD
Control 1 42,024 2447 3107 169 Diarrhea (G1), Skin rash (G2),
fatigue (G3)
PR
Control 2 66,523 3513 5979 306 Skin rash (G1) SD
Control 3 27,727 1572 1315 75 Skin rash (G2), dry skin (G2) PR
Control 4 53,136 2791 11,269 530 Dry skin (G2) PR
Control 5 33,441 1850 2465 126 — PR
AUC0–24, area under the plasma drug concentration-time curve from 0 to 24 h; Cmax, maximal plasma concentration; HD, hemodialysis; G, National Cancer Institute Common
Toxicity Criteria grade; SD, stable disease; PR, partial remission; PD, progressive disease.
Togashi et al. Journal of Thoracic Oncology • Volume 5, Number 5, May 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer604
Erlotinib inhibits the activity of EGFR TKI in intact
tumor cells, with 50% inhibitory concentration values of 20
nmol/liter (7.9 ng/ml).13 In a study of athymic mice with
human carcinomas, the plasma concentration of erlotinib asso-
ciated with 50% inhibition of EGFR TKI was estimated at 8 to
12 mol/liter (3.1–4.7 g/ml).14 Although plasma concentra-
tions exceeded 7.9 ng/ml in all cases, only Cmax on day 8 in
control 2 exceeded 3.1 g/ml. However, he developed progres-
sive disease 8 weeks after administration. The relationship be-
tween tumor response and plasma concentration may be indef-
inite. However, the mean Cmax of all cases, including HD cases,
was 2127 ng/ml, which achieved almost the same plasma con-
centration previously reported.11 The PK data were different
from each other. Especially in HD 3, current smoker, both
AUC0–24 and Cmax of erlotinib on day 8 were lowest and half
period was shortest of all cases. This result is as expected,
because CYP1A1 and CYP1A2 are induced by cigarette smok-
ing.15 There seems to be differences among individuals in the
absorption and the metabolism of erlotinib, which may be
affected by age, other drugs, smoking status, or genetic poly-
morphisms. To assess the pharmacogenomics of erlotinib, more
patients and more PK data are required.
The number of patients undergoing dialysis at the end of
2006, determined on the basis of the survey results from dialysis
facilities, was 264,473 in Japan.16 The prevalence of dialysis of
2007 was 335,963 in the United States.17 The number of patients
undergoing dialysis is expected to increase in the near future.
The increased risk of cancer in a larger cohort of patients
undergoing dialysis was studied by pooled data from United
States Renal Data System, European Dialysis and Transplant
Association, and Australian and New Zealand Dialysis and
Transplant Registry, which included 831,804 patients followed
up for a mean period of 2.5 years. These data reported a
consistent increase in the risk of cervical, bladder, thyroid, and
renal cell carcinoma. There was no significant increase, how-
ever, in the risk of breast, colorectal, and prostate cancers when
compared with the nonchronic kidney disease (CKD) popula-
tion.1 Although there was no significant increase in the risk of
NSCLC, the mortality rate of cancer in subjects with CKD is
expected to increase for the foreseeable future.
Although therapeutic impact on patient survival has been
modest, chemotherapy is the cornerstone for the management of
advanced NSCLC. However, its utility in subjects with CKD has
largely been unstudied, because most cancer drug trials exclude
patients with CKD. Although this report used a small sample,
PK data in the HD group were similar to those in patients with
normal organ function. Moreover, there was no serious adverse
event which supports the effectiveness and safety of erlotinib
treatment for patients with NSCLC undergoing HD. Erlotinib
can become one treatment option for patients with NSCLC and
CRF undergoing HD who are frequently elderly and have poor
PS as seen in our cases.
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